A Study of the Safety and Efficacy of Various Combinations of Avelumab as Therapy in Locally Advanced or Metastatic Urothelial Carcinoma (JAVELIN Bladder Medley)
NCT ID: NCT05327530
Last Updated: 2026-01-26
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
ACTIVE_NOT_RECRUITING
PHASE2
256 participants
INTERVENTIONAL
2022-08-17
2026-06-25
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
A Study Of Avelumab In Patients With Locally Advanced Or Metastatic Urothelial Cancer (JAVELIN Bladder 100)
NCT02603432
A Study to Learn About the Study Medicine (Called Avelumab) in People With Advanced Urothelial Cancer After Chemotherapy
NCT05366725
Copanlisib and Avelumab as a Maintenance Therapy for Advanced Bladder Cancer
NCT05687721
S0353, Gemcitabine in Treating Patients With Recurrent Bladder Cancer That Has Not Responded to Previous Bacillus Calmette-Guerin
NCT00234039
First-line Gemcitabine/Cisplatin +/- Avelumab in Locally Advanced or Metastatic Bladder Carcinoma
NCT03324282
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Group A: Avelumab
Avelumab
Participants will receive avelumab intravenous infusion at a dose of 800 milligrams (mg) once every 2 weeks (Q2W) until unacceptable toxicity, withdraw consent or initiation of a new treatment.
Group B: Avelumab + Sacituzumab Govitecan
Avelumab
Participants will receive avelumab intravenous infusion at a dose of 800 milligrams (mg) once every 2 weeks (Q2W) until unacceptable toxicity, withdraw consent or initiation of a new treatment.
Sacituzumab Govitecan
Participants will receive sacituzumab govitecan intravenous infusion at dose of 10 milligrams per kilogram (mg/kg) of body weight once a week (Q1W) on Day 1 and 8 of 21-day treatment cycles, in combination with avelumab 800 mg Q2W, until unacceptable toxicity, withdraw consent or initiation of a new treatment.
Group C: Avelumab + M6223
Avelumab
Participants will receive avelumab intravenous infusion at a dose of 800 milligrams (mg) once every 2 weeks (Q2W) until unacceptable toxicity, withdraw consent or initiation of a new treatment.
M6223
Participants will receive M6223 (anti-T cell-immuno-receptor with Ig and ITM domains \[anti-TIGIT\]) intravenous infusion at dose of 1600 mg Q2W in combination with avelumab 800 mg Q2W, until unacceptable toxicity, withdraw consent or initiation of a new treatment.
Group D: Avelumab + NKTR-255
Avelumab
Participants will receive avelumab intravenous infusion at a dose of 800 milligrams (mg) once every 2 weeks (Q2W) until unacceptable toxicity, withdraw consent or initiation of a new treatment.
NKTR-255
Participants will receive NKTR-255 intravenous infusion at a dose of 3 micrograms per kilogram body weight (mcg/kg) once every 4 weeks (Q4W) in combination with avelumab 800 mg Q2W, until unacceptable toxicity, withdraw consent or initiation of a new treatment.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Avelumab
Participants will receive avelumab intravenous infusion at a dose of 800 milligrams (mg) once every 2 weeks (Q2W) until unacceptable toxicity, withdraw consent or initiation of a new treatment.
Sacituzumab Govitecan
Participants will receive sacituzumab govitecan intravenous infusion at dose of 10 milligrams per kilogram (mg/kg) of body weight once a week (Q1W) on Day 1 and 8 of 21-day treatment cycles, in combination with avelumab 800 mg Q2W, until unacceptable toxicity, withdraw consent or initiation of a new treatment.
M6223
Participants will receive M6223 (anti-T cell-immuno-receptor with Ig and ITM domains \[anti-TIGIT\]) intravenous infusion at dose of 1600 mg Q2W in combination with avelumab 800 mg Q2W, until unacceptable toxicity, withdraw consent or initiation of a new treatment.
NKTR-255
Participants will receive NKTR-255 intravenous infusion at a dose of 3 micrograms per kilogram body weight (mcg/kg) once every 4 weeks (Q4W) in combination with avelumab 800 mg Q2W, until unacceptable toxicity, withdraw consent or initiation of a new treatment.
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Participants has documented Stage IIIA/IIIB with N1-N3, or Stage IV disease (per American Joint Committee on Cancer/International Union for Cancer Control Tumor Node Metastasis system, 8th edition) at the start of first line chemotherapy.
* The last dose of first line chemotherapy must have been received no less than 4 weeks, and no more than 10 weeks, prior to randomization in the present study
* Estimated life expectancy of at least 3 months
* Participants without progressive disease as per RECIST v1.1 guidelines following completion of 4 to 6 cycles of 1L chemotherapy. Eligibility based on this criterion will be determined by Investigator review of pre chemotherapy and post chemotherapy radiological assessments (CT/MRI scans).
* Eastern Cooperative Oncology Group (ECOG) performance status (PS) 0 or 1
* Adequate hematological, hepatic, and renal function as defined in the protocol
Exclusion Criteria
* Participants with active infection 48 hours before randomization requiring systemic therapy
* Participants with known prior or suspected hypersensitivity to study drugs or any component in their formulations
* Participants with prior adjuvant or neoadjuvant systemic therapy within 12 months of randomization
* Participants with vaccination within 4 weeks of the first dose of study treatment and while on trial is prohibited except for administration of inactivated vaccines (for example, inactivated influenza vaccines) administered \>= 2 weeks prior first dose of study treatment. All severe acute respiratory syndrome coronavirus (SARS-CoV-2) vaccines approved or authorized by local Health Authorities are allowed
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Merck KGaA, Darmstadt, Germany; Gilead Sciences; Nektar Therapeutics
UNKNOWN
EMD Serono Research & Development Institute, Inc.
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Medical Responsible
Role: STUDY_DIRECTOR
Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Beacon Cancer Care
Coeur d'Alene, Idaho, United States
University of Kansas Medical Center Research Institute, Inc. - 3901 Rainbow (MAIN)
Kansas City, Kansas, United States
Johns Hopkins University
Baltimore, Maryland, United States
The Johns Hopkins Hospital
Baltimore, Maryland, United States
AMR Kansas City, Formerly Center for Pharmaceutical Research, an AMR company - Kansas City, MO at St. Joseph Medical Center
Kansas City, Missouri, United States
Seattle Cancer Care Alliance
Seattle, Washington, United States
Multicare Health System Tacoma General Hospital
Tacoma, Washington, United States
University of Wisconsin Cancer Center
Madison, Wisconsin, United States
Flinders Medical Centre
Bedford Park, , Australia
Sunshine Hospital - PARENT
Footscray, , Australia
Ashford Cancer Centre Research
Kurralta Park, , Australia
Liverpool Hospital - PARENT
Liverpool, , Australia
Calvary Mater Newcastle - PARENT
Newcastle, , Australia
Tasman Oncology Research Ltd - Oncology
Southport, , Australia
Macquarie University Hospital - PARENT
Sydney, , Australia
The Kinghorn Can Cen
Westmead, , Australia
ZNA Middelheim - Middelheim - account 2
Antwerp, , Belgium
AZ Klina - PARENT
Brasschaat, , Belgium
Institut Jules Bordet - Medical Oncology
Brussels, , Belgium
Universitair Ziekenhuis Gent - Medical Oncology
Ghent, , Belgium
AZ Groeninge - Campus Kennedylaan - account 2
Kortrijk, , Belgium
Centre Hospitalier de l'Ardenne - PARENT
Libramont, , Belgium
CHU de Liège - PARENT
Liège, , Belgium
Universitaetsklinikum Wuerzburg - Klinik u. Poliklinik f. Urologie u. Kinderurologie
Wuerzburg, , Belgium
William Osler Health System - Brampton Civic Hospital
Brampton, , Canada
CISSS de la Monteregie-Centre - Hospital Charles Le Moyne
Greenfield Park, , Canada
CHUM Centre de Recherche
Montreal, , Canada
The Ottawa Hospital Cancer Centre
Ottawa, , Canada
Hôpital Foch - Service d'Oncologie Médicale
Suresnes, Hauts De Seine, France
ICO - Site Paul Papin - service d'oncologie medicale
Angers, , France
Institut Bergonié - Service d'Oncologie Médicale
Bordeaux, , France
Centre François Baclesse - Pathologies Gynecologiques
Caen, , France
Hôpital Henri Mondor - Service d'Oncologie Médicale
Créteil, , France
Clinique Victor Hugo - Centre Jean Bernard - Service d'Oncologie Médical
Le Mans, , France
Centre Leon Berard - Service d'Oncologie Medicale
Lyon, , France
Hôpital de la Timone - service d'urologie
Marseille, , France
Hopital Caremeau - Service Hématologie Clinique/Oncologie Médicale
Nîmes, , France
Hôpital Cochin - Hematologie et Oncologie Médicale
Paris, , France
CHU Poitiers - Hôpital la Milétrie - service d'oncologie médicale
Poitiers, , France
CRLCC Eugene Marquis - Service d'Oncologie médicale
Rennes, , France
ICO - Site René Gauducheau - Service d'Oncologie medicale
Saint-Herblain, , France
Clinique Sainte-Anne - Service d'Oncologie Médicale
Strasbourg, , France
Institut de Cancérologie de Strasbourg Europe - ICANS - Service d'oncologie médicale
Strasbourg, , France
Kliniken Maria Hilf GmbH - Klinik fuer Urologie
Muenchen, North Rhine-Westphalia, Germany
Universitaetsklinikum Halle (Saale) - Universitaetsklinik und Poliklinik fuer Urologie
Halle, Saxony-Anhalt, Germany
Universitaetsklinikum Essen - Westdeutsches Tumorzentrum
Essen, , Germany
Universitaetsklinikum Frankfurt Goethe-Universitaet - Urologie und Kinderurologie2
Frankfurt, , Germany
Universitaetsklinikum Wuerzburg - Klinik u. Poliklinik f. Urologie u. Kinderurologie
Halle, , Germany
Kliniken Maria Hilf GmbH - Klinik fuer Urologie
Mönchengladbach, , Germany
Universitaetsklinikum Muenster - Klinik und Poliklinik fuer Urologie
Münster, , Germany
Universitaetsklinikum Tuebingen - Klinik fuer Urologie
Tübingen, , Germany
Athens Medical Center
Athens, , Greece
General Hospital of Athens "Alexandra"
Athens, , Greece
University General Hospital "Attikon"
Athens, , Greece
Euromedica General Clinic of Thessaloniki
Thessaloniki, , Greece
Azienda Ospedaliera Universitaria Policlinico Sant'Orsola Malpighi IRCCS - Oncologia Medica
Bologna, , Italy
Azienda Ospedaliera Universitaria Careggi - S.O.D. di Oncologia Medica
Florence, , Italy
IRCCS Istituto Scientifico Romagnolo Per Lo Studio e La Cura Dei Tumori "Dino Amadori" - IRST - Oncologia
Forlì, , Italy
Fondazione IRCCS Istituto Nazionale dei Tumori - S.S. Oncologia Medica Genitourinaria
Milan, , Italy
Ospedale San Raffaele - U.O. di Oncologia Medica
Milan, , Italy
Humanitas Istituto Clinico Catanese - Oncologia Medica
Misterbianco, , Italy
Istituto Nazionale Tumori Fondazione G. Pascale - Oncologia Medica A
Napoli, , Italy
Istituto Nazionale Tumori Regina Elena IRCCS - Urologia
Napoli, , Italy
IOV - Istituto Oncologico Veneto IRCCS - U.O. Oncologia Medica 1
Padua, , Italy
Azienda Ospedaliero Universitaria Pisana - U.O. Oncologia
Pisa, , Italy
Ospedale Santa Maria delle Croci
Ravenna, , Italy
Fondazione Policlinico Universitario Agostino Gemelli IRCCS - UOC Oncologia Medica
Rome, , Italy
IRCCS Ospedale Casa Sollievo della Sofferenza - Dipartimento di Oncologia Medica
San Giovanni Rotondo, , Italy
Azienda Ospedaliera S. Maria Di Terni - S.C. Oncologia Medica
Terni, , Italy
Chungnam National University Hospital - Department of Internal Medicine (Rheumatology)
Daejeon, , South Korea
National Cancer Center
Gyeonggi-do, , South Korea
Seoul National University Bundang Hospital
Seongnam-si, , South Korea
Asan Medical Center
Seoul, , South Korea
Samsung Medical Center
Seoul, , South Korea
Seoul National University Hospital
Seoul, , South Korea
Severance Hospital, Yonsei University Health System
Seoul, , South Korea
The Catholic University of Korea, Seoul St. Mary's Hospital
Seoul, , South Korea
Hospital Infanta Cristina - Unidad de Fase I
Badajoz, , Spain
Hospital Clinic de Barcelona - Servicio de Oncologia
Barcelona, , Spain
Hospital de la Santa Creu i Sant Pau - Dept of Oncology
Barcelona, , Spain
Hospital del Mar - Servicio de Oncologia
Barcelona, , Spain
Hospital Universitario Virgen del Rocio - Oncology Service
Barcelona, , Spain
Hospital Universitario Reina Sofia - Dept of Oncology
Córdoba, , Spain
Hospital General Universitario de Elche - Servicio de Oncologia
Elche, , Spain
Hospital Universitario Lucus Augusti - Oncology
Lugo, , Spain
Hospital General Universitario Gregorio Marañon - Servicio de Oncologia Medica
Madrid, , Spain
ALTHAIA, Xarxa assistencial Universitaria de Manresa - Oncology Dept
Manresa, , Spain
Kaohsiung Chang Gung Memorial Hospital
Kaohsiung City, , Taiwan
Kaohsiung Medical University Chung-Ho Memorial Hospital
Kaohsiung City, , Taiwan
China Medical University Hospital
Taichung, , Taiwan
Chi Mei Hospital, Liouying
Tainan, , Taiwan
National Taiwan University Hospital
Taipei, , Taiwan
Taipei Veterans General Hospital
Taipei, , Taiwan
Chang Gung Memorial Hospital,Linkou
Taoyuan District, , Taiwan
Barts Hospital - Dept of Medical Oncology
London, Greater London, United Kingdom
The Christie Hospital - Dept of Oncology
Manchester, , United Kingdom
Royal Preston Hospital - Rosemere Cancer Centre
Preston, , United Kingdom
Countries
Review the countries where the study has at least one active or historical site.
References
Explore related publications, articles, or registry entries linked to this study.
Naing A, McKean M, Tolcher A, Victor A, Hu P, Gao W, Nogueira Filho MAF, Kitzing T, Gleicher S, Holland D, Richter E, Tadjalli-Mehr K, Siu LL. TIGIT inhibitor M6223 as monotherapy or in combination with bintrafusp alfa in patients with advanced solid tumors: a first-in-human, phase 1, dose-escalation trial. J Immunother Cancer. 2025 Feb 10;13(2):e010584. doi: 10.1136/jitc-2024-010584.
Hoffman-Censits J, Grivas P, Powles T, Hawley J, Tyroller K, Seeberger S, Guenther S, Jacob N, Mehr KT, Hahn NM. The JAVELIN Bladder Medley trial: avelumab-based combinations as first-line maintenance in advanced urothelial carcinoma. Future Oncol. 2024 Feb;20(4):179-190. doi: 10.2217/fon-2023-0492. Epub 2023 Sep 6.
Related Links
Access external resources that provide additional context or updates about the study.
Trial Awareness and Transparency website
US Medical Information website, Medical Resources
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
2021-003669-36
Identifier Type: EUDRACT_NUMBER
Identifier Source: secondary_id
2023-510139-12-00
Identifier Type: CTIS
Identifier Source: secondary_id
MS100070_0119
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.